Quality Control and Evaluation in Standard COPD Management

There is lack of quality control and evaluation indexes for standard COPD management in hospitals in China, leading to nonstandard in COPD management and discrepancy in therapeutic efficiency. This study focuses on establishing quality control and evaluation indexes for standard COPD management in hospitals in China, and evaluating the therapeutic efficiency after standard COPD management. This part is a prospective cohort which lasts 2 years. After standard COPD management according to GOLD 2017 by doctors in hospitals in China, patients will be followed up for their outcome after 1 year. Several indexes will be selected to evaluate the quality control of standard COPD management and its efficiency. The controls are from hospital-based subjects with a retrospective cohort study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COPD Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

TongjiChibi hospital, Chibi, Hubei, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1.Clinical manifestation of COPD; post bronchodilator FEV1/FVC<0.70

Exclusion criteria

1. lung cancer. 2. Any history of psychiatric disorders. 3.HIV positive. 4.Breastfeeding, pregnancy or planning to be pregnant. 5.Estimated lifetime less than 1 years due to underlying diseases.

Treatment and study plan

GOLD 2017

Other

Standard COPD management according to GOLD 2017, and control the quality of management in one-year follow-up.

Primary outcomes

Change in spirometry

Time frame: 1 years

Spirometry will be assessed at baseline and through study completion

Secondary outcomes

Morbidity of acute exacerbation in 1 years

Time frame: 1 year

Morbidity of acute exacerbation completion will be assessed at baseline and through study

Sponsors and collaborators

Lead sponsor

Tongji Hospital

Other

Collaborators

Central health center in Yongjiahe Town,China
Chinses PLA general hospital
First Affiliated Hospital Xi'an Jiaotong University
First Hospital of China Medical University
Guilin Medical University, China
Huashan Hospital
Jing-An District Center Hospital of Shanghai (Huashan Hospital Fudan University Jing-An Branch), Shanghai Medical College, Fudan University
Peking University Third Hospital
Second Xiangya Hospital of Central South University
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai Xuhui Central Hospital
Shanghai Zhongshan Hospital
Sijing hospital of Songjiang District in Shanghai
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Tong Ren hospital Shanghai Jiao Tong university school of medicine
TongjiChibi hospital,China
University hospital of Hubei university for nationalities,China
Yiwu Central Hospital
Youxian People's Hospital
Zhejiang Putuo Hospital

Registry information

Important dates

Study start: 2017
Primary completion: 2019
Study completion: 2019
First posted: Oct 19, 2017
Registry last updated: Mar 25, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed